LA JOLLA, Calif. (AP) _ Orexigen Therapeutics Inc. (OREX) on Tuesday reported a loss of $24.6 million in its fourth quarter.
The La Jolla, California-based company said it had a loss of $1.69 per share. Losses, adjusted for one-time gains and costs, came to $2.67 per share.
The drug developer for obesity and weight loss posted revenue of $13.9 million in the period.
For the year, the company reported that its loss narrowed to $24.5 million, or $1.68 per share. Revenue was reported as $33.7 million.
In the final minutes of trading on Tuesday, the company's shares hit $4.24. A year ago, they were trading at $5.22.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on OREX at https://www.zacks.com/ap/OREX
Keywords: Orexigen Therapeutics, Earnings Report